

RECEIVED

OCT 22 2002

TECH CENTER 1600/2900

EXPRESS MAIL CERTIFICATE

Date 10/16/02 Label No. EV208552478

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.:



Docket No: 0630/1E791-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Vedrana S. SUSULIC; Emir DUZIC

Serial No.: 09/761,116

Art Unit: 1636

Confirmation No.: 3094

Filed: January 16, 2001

Examiner: Leffers Jr., Gerald

For: TRANSCRIPTIONAL REGULATION OF THE HUMAN BETA3 - ADRENERGIC RECEPTOR GENE

COURTESY COPY OF CLAIMS PENDING UPON
ENTRY OF ACCOMPANYING AMENDMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

October 16, 2002

Sir:

28. (Amended) A method of screening for a compound that increases activity of an Sp1 or B segment-binding β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

(a) contacting cells capable of producing the Sp1 or B segment-binding β_3 -AR *trans*-activating factor with a test compound; and

(b) detecting an increase in a level of activity of the Sp1 or B segment-binding β_3 -AR *trans*-activating factor.

29. (Amended) A method of screening for a compound that increases activity of a β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

(a) contacting cells capable of producing the β_3 -AR *trans*-activating factor with a test compound; and

(b) detecting an increase in a level of activity of the β_3 -AR *trans*-activating factor, wherein the increase in the level of activity of the β_3 -AR *trans*-activating factor is detected by detecting an increase in the level of expression of a reporter gene operatively associated with an isolated nucleic acid having a nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) relative to a level of expression prior to contact with the test compound.

30. (Amended) A method according to claim 28, wherein the increase in the level of activity of the β_3 -AR *trans*-activating factor is detected by detecting an increase in the amount of β_3 -AR *trans*-activating factor present in the cells after contacting them with the test compound relative to the amount present prior to contact with the test compound.

31. A method according to claim 28, wherein the cells do not endogenously express, or express at very low level, β_3 -AR.

32. A method according to claim 31, wherein the cells are selected from the group consisting of HeLa cells, CV-1 cells, and WAT cells.

33. (Amended) A method of screening for a compound that inhibits activity of an Sp1 or B segment-binding β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

(a) contacting cells capable of producing the Sp1 or B segment-binding β_3 -AR *trans*-activating factor with a test compound;
and

(b) detecting a decrease in a level of activity of the Sp1 or B segment-binding β_3 -AR *trans*-activating factor.

34. (Amended) A method of screening for a compound that inhibits activity of a β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

- (a) contacting cells capable of producing the β_3 -AR *trans*-activating factor with a test compound; and
- (b) detecting a decrease in a level of activity of the β_3 -AR *trans*-activating factor,

wherein the decrease in the level of activity of the β_3 -AR *trans*-activating factor is detected by detecting a decrease in the level of expression of a reporter gene operatively associated with an isolated nucleic acid having a nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) relative to a level of expression prior to contact with the test compound.

35. A method according to claim 33, wherein the decrease in the level of activity of the β_3 -AR *trans*-activating factor is detected by detecting a decrease in the amount of β_3 -AR *trans*-activating factor present in the cells after contacting them with the test compound relative to the amount present prior to contact with the test compound.

36. A method according to claim 33, wherein the cells endogenously express β_3 -AR.

37. A method according to claim 36, wherein the cells are selected from the group consisting of neuroblastoma and BAT cells.

38. (New). A method of screening for a compound that increases activity of a β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

(a) contacting cells capable of producing the β_3 -AR *trans*-activating factor with a test compound; and

(b) detecting an increase in a level of activity of the β_3 -AR *trans*-activating factor,

wherein the level of activity of the β_3 -AR *trans*-activating factor is detected by an increase in the level of expression of a reporter gene operatively associated with an isolated nucleic acid selected from the group consisting of:

(i) about a 7 kb genomic DNA 5' flanking region of a β_3 -AR transcription start site,

(ii) a deletion construct of a 7 kb genomic DNA located upstream of a β_3 -AR transcription start site;

(iii) a nucleic acid wherein the sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) is located 5' to the Sp-1 binding site relative to a transcription start site; and

(iv) a nucleic acid comprising a heterologous coding sequence

operatively associated with a promoter and operatively associated with the nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) in proximity to the Sp-1 binding site, whereby expression of the heterologous protein is regulated in a tissue specific manner.

39. (New) A method of screening for a compound that decreases activity of a β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

- (a) contacting cells capable of producing the β_3 -AR *trans*-activating factor with a test compound; and
- (b) detecting an decrease in a level of activity of the β_3 -AR *trans*-activating factor,

wherein the level of activity of the β_3 -AR *trans*-activating factor is detected by an decrease in the level of expression of a reporter gene operatively associated with an isolated nucleic acid selected from the group consisting of:

- (i) about a 7 kb genomic DNA 5' flanking region of a β_3 -AR transcription start site,
- (ii) a deletion construct of a 7 kb genomic DNA located upstream of a β_3 -AR transcription start site;
- (iii) a nucleic acid wherein the sequence that is greater than 80%

identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) is located 5' to the Sp-1 binding site relative to a transcription start site; and

(iv) a nucleic acid comprising a heterologous coding sequence operatively associated with a promoter and operatively associated with the nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) in proximity to the Sp-1 binding site, whereby expression of the heterologous protein is regulated in a tissue specific manner.

M:\0630\1e791us1\HME0379.WPD